Brought to you by 
MassGen licenses CRISPR/Cas9/TALENS IP to Editas
21 Apr 2020
Executive Summary
Massachusetts General Hospital licensed Editas Medicine Inc. exclusive rights to IP and technology related to genome editing research done by Editas scientific founder and advisor J. Keith Joung, MD, PhD, who is the associate chief of pathology for research at MassGen.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MassGen licenses CRISPR/Cas9/TALENS IP to Editas
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice